873 related articles for article (PubMed ID: 27129866)
21. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
[TBL] [Abstract][Full Text] [Related]
22. Low-dose High-resolution
Ferdová E; Baxa J; Ňaršanská A; Hes O; Fínek J; Topolčan O; Ferda J
Anticancer Res; 2018 Jul; 38(7):4145-4148. PubMed ID: 29970542
[TBL] [Abstract][Full Text] [Related]
23. The value of 18F-FDG PET/CT imaging in breast cancer staging.
Yararbas U; Avci NC; Yeniay L; Argon AM
Bosn J Basic Med Sci; 2018 Feb; 18(1):72-79. PubMed ID: 28763628
[TBL] [Abstract][Full Text] [Related]
24. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
[TBL] [Abstract][Full Text] [Related]
25. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
26. Correlation of hypoxia inducible transcription factor in breast cancer and SUVmax of F-18 FDG PET/CT.
Jeong YJ; Jung JW; Cho YY; Park SH; Oh HK; Kang S
Nucl Med Rev Cent East Eur; 2017; 20(1):32-38. PubMed ID: 28198519
[TBL] [Abstract][Full Text] [Related]
27. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
28. Association between MRI Features and Standardized Uptake Value of 18F-FDG PET/CT in Triple-Negative Breast Cancer.
Choi BB; Lee JS; Kim KH
Oncol Res Treat; 2018; 41(11):706-711. PubMed ID: 30321870
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
30.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
31. Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes.
Jeong YJ; Kang DY; Yoon HJ; Son HJ
Breast Cancer Res Treat; 2014 May; 145(1):137-42. PubMed ID: 24682676
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment
Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
[TBL] [Abstract][Full Text] [Related]
33. ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A; Dygai-Cochet I; Riedinger JM; Humbert O; Berriolo-Riedinger A; Toubeau M; Guiu S; Coutant C; Coudert B; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):428-37. PubMed ID: 24196916
[TBL] [Abstract][Full Text] [Related]
34. PET/CT with
Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
[TBL] [Abstract][Full Text] [Related]
35. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
[TBL] [Abstract][Full Text] [Related]
36. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
37. Chest radiography or chest CT plus head and neck CT versus
Kim Y; Roh JL; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY
Oral Oncol; 2019 Jan; 88():109-114. PubMed ID: 30616780
[TBL] [Abstract][Full Text] [Related]
38. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
Cermik TF; Mavi A; Basu S; Alavi A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366
[TBL] [Abstract][Full Text] [Related]
39. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
